Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Vaxcyte, Inc.

Vaxcyte, Inc. (PCVX) Stock Overview

Explore Vaxcyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PCVX●NASDAQ
HealthcareBiotechnology
$62.62
$1.28(2.09%)
U.S. Market opens in 58h 46m

Vaxcyte, Inc. (PCVX)

Meyka AI Score

Z

Key Financials

Market Cap9B
P/E Ratio-8.23
EPS (TTM)$-7.63
ROE-0.38%
Fundamental Analysis

AI Price Forecasts

1 Month$58.92
3 Months$91.27
1 Year Target$49.10

PCVX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Vaxcyte, Inc. (NASDAQ: PCVX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Vaxcyte, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PCVX on the NASDAQ shows an RSI of 63.29, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $49.10 for the NASDAQ listing.

Key metrics behind Vaxcyte, Inc.'s NASDAQ-traded stock include a P/E ratio of -8.23 and a market capitalization of 9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PCVX on the NASDAQ.

Price Performance (NASDAQ: PCVX)

1-Day Change
2.09%
5-Day Change
7.76%
1-Month Change
7.89%
3-Month Change
32.14%
6-Month Change
7.02%
Year-to-Date (YTD) Change
35.72%
1-Year Change
96.24%
3-Year Change
25.97%
5-Year Change
167.72%
All-Time (Max) Change
139.46%

Contact Information

https://vaxcyte.com
650 837 0111
825 Industrial Road, San Carlos, CA, 94070

Company Facts

5,070 Employees
IPO DateJun 12, 2020
CountryUS
Actively Trading

Frequently Asked Questions